A practical reference on growth hormone secretagogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Plastic surgery can be performed to augment or reduce the size of breasts, or to reconstruct the breast in cases of deformative disease, such as breast cancer. Breast augmentation and breast lift (mastopexy) procedures are done only for cosmetic reasons, whereas breast reduction is sometimes medically indicated. In cases where a woman's breasts are severely asymmetrical, surgery can be performed to either enlarge the smaller breast, reduce the size of the larger breast, or both. Breast augmentation surgery generally does not interfere with future ability to breastfeed. Breast reduction surgery more frequently leads to decreased sensation in the nipple-areola complex, and to low milk supply in women who choose to breastfeed. Implants can interfere with mammography (breast x-ray images).
Maximum levels for baby foods and chocolate/cocoa products were established under Commission Regulation (EU) No 488/2014. 1986 California Proposition 65 requires a warning label on chocolate products having more than 4.1 mg of cadmium per daily serving of a single product.
The Army Reserve is the volunteer reserve force of the British Army. It is separate from the Regular Reserve whose members are ex-regular personnel who retain a statutory liability for service. Descended from the Territorial Force (1908 to 1921), the Army Reserve was known as the Territorial Army (TA) from 1921 to 1967 and again from 1979 to 2014, and the Territorial and Army Volunteer Reserve (TAVR) from 1967 to 1979. The force was created in 1908 by the Secretary of State for War, Richard Haldane, when the Territorial and Reserve Forces Act 1907 combined the previously civilian-administered Volunteer Force, with the mounted Yeomanry (at the same time the Militia was renamed the Special Reserve). Haldane planned a volunteer "Territorial Force", to provide a second line for the six divisions of the Expeditionary Force which he was establishing as the centerpiece of the Regular Army. The Territorial Force was to be composed of fourteen divisions of infantry and fourteen brigades of cavalry, together with all the supporting arms and services needed for overseas war, including artillery, engineers, commissariat and medical support. The new Special Reserve was to take over the depots of the militia, as an expanded reserve for the Regular Army. Under multiple political pressures, Haldane made a last-minute alteration to his Territorial and Reserve Forces Act; the public purpose of the Territorial Force was changed to home defence, although its planned structure was left intact.
Sources: en.wikipedia.org
Nando's opened its first restaurant location within the United States in Washington, D.C. in 2008. After opening more outlets within the Washington metropolitan area, it expanded into the Chicago metropolitan area, opening its first outlet on 20 May 2015 within the metro area. As of February 2026, there are 46 restaurant outlets in five states and the District of Columbia: 12 in Illinois, six in Washington, D.C., 10 in Maryland, 11 in Virginia, two in Georgia, and five in Texas.
==== Danish ==== Danish Brotherhood in America Danish Sisterhood - Founded December 15, 1883, in Negaunee, Michigan, by Mrs. Christine Hemmingsen. A supreme lodge was formed in 1887, and all the officers were women by 1910. Membership was open to women of Danish descent or married to a man of Danish descent. Admission is by black ball, with one blackball enough to disqualify; there is always a second ballot; if there is another blackball a selected secret committee is appointed to determine the cause. Had a secret ritual, and no uninitiated person may attend secret meetings of the lodge. Locals are called "lodges"; regional groups are called "Districts". National convention meets quadrennially. Supreme Lodge headquarters is in Chicago. Provides funeral benefits of up to $1,000, no more than two beneficiaries can be designated, and in special circumstances, other benefits can be applied for. Membership in 1922, 8,000, 1934, 7,000, and 1979, 4,500.
===== The maxillary division innervation ===== Maxillary nerve – conveys sensation to the upper jaw and the face. Infraorbital nerve – conveys sensation to the area from below the eye socket to the external nares (nostrils). Zygomatic nerve – through the zygomatic bone and the zygomatic arch, conveys sensation to the cheekbone areas. Superior posterior dental nerve – sensation in the teeth and the gums. Superior anterior dental nerve – mediates the sneeze reflex. Sphenopalatine nerve – divides into the lateral branch and the septal branch, and conveys sensation from the rear and the central regions of the nasal cavity.
In October 2013, A&W opened its first new concept restaurant, A&W Burgers Chicken Floats. The new concept focuses on fresh made-to-order food and heavily emphasizes customer service. The menu features burgers made with fresh beef and a choice of toppings, hand-breaded chicken tenders, all-beef hot dogs, and several sides. The new management gave A&W a significant boost in the number of locations, with 2017 scheduled to have more openings than closures. For 2018, A&W projected an increase in its franchising operations and opening new restaurants. In April 2019, A&W returned to Singapore after a 16-year absence, its first location being at Jewel Changi Airport. In June 2019, the A&W chain started moving its headquarters to the University of Kentucky Coldstream Research Campus in 2019. A&W announced in March 2022 that it was going to withdraw from the Thai market due to economic losses. The restaurants shut down on March 20. A franchise was given to western New York in early 2023, with three locations, the first of which in Niagara Falls, set to open between May and June of that year. There are nearly 1,000 A&W Restaurants worldwide that are owned or franchised through A Great American Brand, with approximately 475 of these restaurants located in the U.S. as of October 2024. A&W rebounded its profits in the first half of 2024, emphasis on its growth is given mainly to single-brand restaurants, as well as restaurants in less conventional locations. In November 2024, the chain announced its entrance to the Milwaukee and Madison markets in Wisconsin.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.